Sung H, Ferlay J, Siegel RL. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
Bossi P, Chan AT, Licitra L, Trama A, Orlandi E, Hui EP, Halámková J, Mattheis S, Baujat B, Hardillo J, et al. Nasopharyngeal carcinoma: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up(†). Ann Oncol Off J Eur Soc Med Oncol. 2021;32(4):452–65.
Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet (London, England). 2019;394(10192):64–80.
Zhi-Qiang W, Qi M, Ji-Bin L, Rui Y, You-Ping L, Rui S, Guang-Yuan H, Ming-Yuan C, Yi-Jun H. The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis. BMC Cancer. 2019;19(1):1122.
Bian X, Song T, Wu S. Outcomes of xerostomia-related quality of life for nasopharyngeal carcinoma treated by IMRT: based on the EORTC QLQ-C30 and H&N35 questionnaires. Expert Rev Anticancer Ther. 2015;15(1):109–19.
Li JB, Guo SS, Tang LQ, Guo L, Mo HY, Chen QY, Mai HQ. Longitudinal trend of health-related quality of life during concurrent chemoradiotherapy and survival in patients with stage II-IVb nasopharyngeal carcinoma. Front Oncol. 2020;10: 579292.
Dancey J, Zee B, Osoba D, Whitehead M, Lu F, Kaizer L, Latreille J, Pater JL. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res Int J Qual Life Aspects Treatment Care Rehabil. 1997;6(2):151–8.
Ringdal GI, Götestam KG, Kaasa S, Kvinnsland S, Ringdal K. Prognostic factors and survival in a heterogeneous sample of cancer patients. Br J Cancer. 1996;73(12):1594–9.
Menon N, Patil V, Noronha V, Joshi A, Bhattacharjee A, Satam BJ, Mathrudev V, Ghosh Laskar S, Prabhash K. Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone – Additional data from a phase 3 trial. Oral Oncol. 2021;122: 105517.
Coates A, Porzsolt F, Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer. 1997;33(7):1025–30.
Langendijk H, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Wouters M. The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2000;55(1):19–25.
Wisløff F, Hjorth M. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol. 1997;97(1):29–37.
Blazeby JM, Brookes ST, Alderson D. The prognostic value of quality of life scores during treatment for oesophageal cancer. Gut. 2001;49(2):227–30.
Kramer JA, Curran D, Piccart M, de Haes JC, Bruning P, Klijn J, Van Hoorebeeck I, Paridaens R. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer. 2000;36(12):1498–506.
Guo SS, Hu W, Chen QY, Li JM, Zhu SH, He Y, Li JW, Xia L, Ji L, Lin CY, et al. Pretreatment quality of life as a predictor of survival for patients with nasopharyngeal carcinoma treated with IMRT. BMC Cancer. 2018;18(1):114.
van Nieuwenhuizen AJ, Buffart LM, Langendijk JA, Vergeer MR, Voortman J, Leemans CR, Verdonck-de Leeuw IM. Health-related quality of life and overall survival: a prospective study in patients with head and neck cancer treated with radiotherapy. Qual Life Res. 2021;30(4):1145–53.
Ediebah DE, Galindo-Garre F, Uitdehaag BM, Ringash J, Reijneveld JC, Dirven L, Zikos E, Coens C, van den Bent MJ, Bottomley A, et al. Joint modeling of longitudinal health-related quality of life data and survival. Qual Life Res. 2015;24(4):795–804.
Ibrahim JG, Chu H, Chen LM. Basic concepts and methods for joint models of longitudinal and survival data. J Clin Oncol. 2010;28(16):2796–801.
Desmée S, Mentré F, Veyrat-Follet C, Guedj J. Nonlinear mixed-effect models for prostate-specific antigen kinetics and link with survival in the context of metastatic prostate cancer: a comparison by simulation of two-stage and joint approaches. AAPS J. 2015;17(3):691–9.
Asar Ö, Ritchie J, Kalra PA, Diggle PJ. Joint modelling of repeated measurement and time-to-event data: an introductory tutorial. Int J Epidemiol. 2015;44(1):334–44.
Tang LQ, Chen DP, Guo L, Mo HY, Huang Y, Guo SS, Qi B, Tang QN, Wang P, Li XY, et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2018;19(4):461–73.
Vanbutsele G, Van Belle S, Surmont V, De Laat M, Colman R, Eecloo K, Naert E, De Man M, Geboes K, Deliens L, et al. The effect of early and systematic integration of palliative care in oncology on quality of life and health care use near the end of life: a randomised controlled trial. Eur J Cancer. 2020;124:186–93.
Klinkhammer-Schalke M, Steinger B, Koller M, Zeman F, Fürst A, Gumpp J, Obermaier R, Piso P, Lindberg-Scharf P. Diagnosing deficits in quality of life and providing tailored therapeutic options: Results of a randomised trial in 220 patients with colorectal cancer. Eur J Cancer. 2020;130:102–13.
Chesnaye NC, Tripepi G, Dekker FW, Zoccali C, Zwinderman AH, Jager KJ. An introduction to joint models-applications in nephrology. Clin Kidney J. 2020;13(2):143–9.
Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139–44.
Garcia-Hernandez A, Rizopoulos D. JM: a SAS macro to fit jointly generalized mixed models for longitudinal data and time-to-event responses. J Stat Softw. 2018;84(12):1–29.
Chen LM, Yang QL, Duan YY, Huan XZ, He Y, Wang C, Fan YY, Cai YC, Li JM, Chen LP, et al. Multidimensional fatigue in patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: incidence, severity, and risk factors. Support Care Cancer. 2021;29(9):5009–19.
Rodríguez Antolín A, Martínez-Piñeiro L, Jiménez Romero ME, García Ramos JB, López Bellido D, Muñoz Del Toro J, García García-Porrero A, Gómez Veiga F. Prevalence of fatigue and impact on quality of life in castration-resistant prostate cancer patients: the vital study. BMC Urol. 2019;19(1):92.
Xiao C, Eldridge RC, Beitler JJ, Higgins KA, Chico CE, Felger JC, Wommack EC, Knobf T, Saba NF, Shin DM, et al. Association among glucocorticoid receptor sensitivity, fatigue, and inflammation in patients with head and neck cancer. Psychosom Med. 2020;82(5):508–16.
Weber D, O’Brien K. Cancer and cancer-related fatigue and the interrelationships with depression, stress, and inflammation. J Evidence-based Complement Alternat Med. 2017;22(3):502–12.
Klimas NG, Broderick G, Fletcher MA. Biomarkers for chronic fatigue. Brain Behav Immun. 2012;26(8):1202–10.
Sandfeld-Paulsen B, Aggerholm-Pedersen N, Winther-Larsen A. Hyponatremia in lung cancer: Incidence and prognostic value in a Danish population-based cohort study. Lung cancer (Amsterdam, Netherlands). 2021;153:42–8.
Tiseo M, Buti S, Boni L, Mattioni R, Ardizzoni A. Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan. Lung cancer (Amsterdam, Netherlands). 2014;86(1):91–5.
Hefler-Frischmuth K, Grimm C, Gensthaler L, Reiser E, Schwameis R, Hefler LA. Prognostic value of preoperative hyponatremia and thrombocytosis in patients with epithelial ovarian cancer. Wien Klin Wochenschr. 2018;130(19–20):575–80.
Xu J, Chen X, Wang X, Zhu C, Hu Y, Yang X, Xu C, Shen X. Preoperative hyponatremia and hypocalcemia predict poor prognosis in elderly gastric cancer patients. Cancer Manag Res. 2019;11:8765–80.
Castillo JJ, Glezerman IG, Boklage SH, Chiodo J 3rd, Tidwell BA, Lamerato LE, Schulman KL. The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients. BMC Cancer. 2016;16:564.
Workeneh BT, Jhaveri KD, Rondon-Berrios H. Hyponatremia in the cancer patient. Kidney Int. 2020;98(4):870–82.
Chapman KM, Nelson RA. Loss of appetite: managing unwanted weight loss in the older patient. Geriatrics. 1994;49(3):54–9.
Behl D, Jatoi A. Pharmacological options for advanced cancer patients with loss of appetite and weight. Expert Opin Pharmacother. 2007;8(8):1085–90.
Du XJ, Tang LL, Mao YP, Guo R, Sun Y, Lin AH, Ma J. Value of the prognostic nutritional index and weight loss in predicting metastasis and long-term mortality in nasopharyngeal carcinoma. J Transl Med. 2015;13:364.
Ghadjar P, Hayoz S, Zimmermann F, Bodis S, Kaul D, Badakhshi H, Bernier J, Studer G, Plasswilm L, Budach V, et al. Impact of weight loss on survival after chemoradiation for locally advanced head and neck cancer: secondary results of a randomized phase III trial (SAKK 10/94). Radiat Oncol (London, England). 2015;10:21.
Liu Y, Cao X. Immunosuppressive cells in tumor immune escape and metastasis. J Mol Med (Berl). 2016;94(5):509–22.
Kitamura T, Qian BZ, Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol. 2015;15(2):73–86.
Add Comment